Deep Intelligence Across Industries

Zydus Lifesciences is transitioning from a volume generics exporter into a branded, innovation-weighted global life-sciences company. Management states that branded products now exceed 55% of consolidated revenue and that branded sales within the United States have reached 11% (Q1 FY27). The company is the third-largest generic pharmaceutical company in the US by prescription volume, holds a top-tier position in Indian branded formulations with leadership in oncology, and owns India's most commercially credible new-chemical-entity franchise in Lipaglyn (saroglitazar) and Oxemia (desidustat). FY26 revenue of ₹27,148 crore (~US$3.07 billion) was the company's highest ever, with a record 31.2% EBITDA margin. Three inorganic moves in eighteen months — Comfort Click in consumer wellness, Amplitude Surgical in orthopaedic devices, Agenus' California biologics plants and Assertio in US specialty oncology — have simultaneously diversified the earnings base and, for the first time in a decade, levered the balance sheet. The central investment question is whether specialty and biosimilar scale-up outruns Revlimid and Mirabegron erosion. Zydus Lifesciences Limited is the listed flagship of the Ahmedabad-based Zydus Group and India's fifth-to-sixth largest pharmaceutical company by revenue. It is a vertically integrated, increasingly innovation-led life-sciences business spanning branded formulations in India, generics and specialty pharmaceuticals in North America, emerging-market and European formulations, active pharmaceutical ingredients, consumer wellness (through the separately listed subsidiary Zydus Wellness), medical technology, vaccines, biosimilars and — since January 2026 — US-based biologics contract manufacturing. --- **What the company does.** Zydus discovers, develops, manufactures and markets a broad range of healthcare therapies: small-molecule generics, branded prescription formulations, biologics and biosimilars, vaccines, active pharmaceutical ingredients, consumer wellness products, and — most recently — orthopaedic implants and biologics contract manufacturing services. The company's own framing, repeated verbatim in its earnings releases, is that of "an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies," operating under "an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives." **Independent characterisation.** Zydus is best understood as four businesses of very different economic character stapled to a common Indian manufacturing and R&D base: 1. **A US generics volume machine (~40-44% of revenue).** Commodity-priced, high-working-capital, exposed to distributor consolidation and price erosion, but defended by scale — 513 cumulative ANDA filings and 448 approvals as at 30 June 2026 — and by first-to-file/CGT exclusivity opportunism. Earnings here are lumpy and event-driven, dominated in recent years by generic Revlimid (lenalidomide) and generic Myrbetriq (mirabegron), both of which are now rolling off. 2. **An Indian branded prescription franchise (~24-25% of revenue).** Annuity-like, chronic-weighted, priced above generics, with distribution scale and physician relationships as the moat. Chronic and sub-chronic therapies reached 54.2% of the India book by MAT June 2026 (AWACS), up 360 basis points over four years. 3. **A consumer wellness FMCG business (~15-20% of revenue).** Held through the separately listed Zydus Wellness Limited. Brand-driven, seasonal, low regulatory risk, and — since Comfort Click — increasingly a cross-border e-commerce/D2C vitamins business rather than a purely Indian one. 4. **An emergent specialty/innovation portfolio.** Rare disease (Zycubo, Nulibry via Sentynl), 505(b)(2) reformulations (Beizray), biosimilars (Nufymco, Tishtha, Anyra), NCEs (saroglitazar, desidustat, zintrodiazine), MedTech (Amplitude Surgical) and CDMO (Zylidac Bio). This is where management is directing incremental capital, and where none of the assets is yet individually material to consolidated revenue. **Revenue model.** Overwhelmingly product sales rather than services or subscription. Three secondary streams exist: (a) out-licensing income — desidustat was licensed to China Medical System Holdings in 2020 and reached Chinese approval in FY26; (b) alliance/contract income, reported as "Alliances & Others" and now near-immaterial at ₹571 million in FY26 (down 64% year on year); and (c) from FY27, contract development and manufacturing fees through Zylidac Bio LLC, which carries an exclusive manufacturing arrangement with Agenus for botensilimab and balstilimab plus a first right of negotiation on Agenus' future pipeline. **Value chain position.** Unusually integrated for an Indian pharmaceutical company: captive API manufacture (with the pending Sterling Biotech API acquisition intended to deepen this), formulation manufacture across 44 facilities, in-house biologics drug substance and drug product capability, its own US front-end distribution (Zydus Pharmaceuticals USA, Viona, Sentynl, Zydus Therapeutics), and now US-domiciled biologics manufacturing. **Customer types and end-markets.** In India: distributors and stockists selling into ~800,000 retail pharmacies, plus hospitals and institutional/government tenders (notably vaccines). In the US: the three large drug purchasing consortia and wholesalers (whose bargaining power drives the group's 188-day gross current asset cycle), plus specialty pharmacy and buy-and-bill oncology channels for Rolvedon and the biosimilars. In emerging markets and Europe: a mix of own subsidiaries (France, Spain, Brazil, South Africa, Mexico, Philippines, Sri Lanka, Myanmar) and third-party distributors. In consumer wellness: modern trade, general trade, e-commerce and, post-Comfort Click, direct-to-consumer digital channels in the UK, EU and US.

Company Headquarters: New York, US Founded: 2007 Workforce: 7000+ Company Working: Carestream Health is a medical imaging and information technology health company. The company develops diagnostic tools such as digital X-ray machines, mammography equipment, radiography, molecular imaging, and related supplies. It has strong research and development department and holds more than 600 patents in the area of digital imaging, healthcare IT, film, and imaging chemistry. It is present in all the major markets and covers more than 150 countries.

Company Headquarters: New York, US Founded: 1946 Workforce: ~46,000 Company Working: Estée Lauder Inc. offers skincare, makeup, and fragrance products. The company has brands, namely, AERIN, Aramis, Aveda, BECCA, Bobbi Brown, Bumble and bumble, By Kilian, Clinique, Darphin, Donna Karan New York, DKNY, Editions de Parfums Frédéric Malle, Ermenegildo Zegna, Estée Lauder, GLAMGLOW, Jo Malone London, Kiton, La Mer, Lab Series, Le Labo, M•A•C, Michael Kors, Origins, Prescriptives, RODIN olio Lusso, Smashbox, Tom Ford, Tommy Hilfiger, Too Faced and Tory Burch. Its products are sold in more than 135 countries and territories.

Company Headquarters: Tel Aviv-Yafo, Israel Founded: 1968 Workforce: ~12,600 Company Working: Israel Chemicals Ltd (ICL), together with its subsidiaries, is involved in the production of magnesium hydroxide. The company operates through two business segments—namely essential minerals and specialty solutions. The essential minerals segment is further divided into potash and magnesium, phosphate, and specialty fertilizers. The specialty solutions segment is further sub-segmented into industrial products, advanced additives, and food specialties. Under specialty solutions, its subsidiary, ICL Industrial Products, produces magnesium oxide and is a global leader in specialty magnesia which is used in agriculture, construction, environmental, and general chemical grades. It sells its products through marketing companies, agents, and distributors.

COMPANY OVERVIEW Company Headquarters: Indiana, US Founded: 1912 Workforce: ~1,157 Company Working: HAYNES INTERNATIONAL (Haynes International) is one of the leading manufacturers and distributors of highperformance nickel‐ and cobalt‐based alloys for corrosion resistant and high-temperature applications. The company offers alloys in various forms including sheet, plate, bar, billet, seamless and welded pipe and tubing, fittings and flanges. It supplies high-performance alloys to the aerospace, power, chemical, wastewater treatment, and pharmaceutical industries. It operates through two business segments, namely corrosion-resistant alloys and high-temperature resistant alloys. Under the high-temperature resistant alloys segment, the company offers superalloys for hot sections of gas turbine engines in the aerospace and energy industries. Through the corrosion-resistant alloys segment, it offers superalloys for chemical processing and power plant emissions control. The high performance alloys are majorly sold under the brand names HAYNES and HASTELLOY. The company has six manufacturing facilities located in the US, and direct sales presence across the US, China, Japan, Singapore, the UK, Italy, France, and Switzerland.

Company Headquarters: Linköping, Sweden Founded: 1978 Workforce: 706 Company Working: Sectra AB (Sectra) is a technology company based in Sweden. The company has customers in around 60 countries, out of which it sells its products directly in 19 countries and via partners in remaining countries. Sectra AB operates through four operating segments, namely, imaging IT solutions, secure communications, business innovation, and spectra customer financing. The imaging IT solutions segment manufactures and sells medical IT systems and services, and also offers maintenance in the form of support, business development, system monitoring, system design, and consulting services related to integration and data migration.

Company Headquarters: Kagawa, Japan Founded: 1947 Workforce: ~24 Company Working: Kyowa Chemical Industry Co., Ltd (Kyowa) is engaged in the production and marketing of magnesium hydroxide. The magnesium hydroxide is utilized in a wide range of applications, including industrial, pharmaceutical and food additives. The company accounted for sales revenue worth USD 190.0 Million in 2018.

Company Headquarters: Hamburg, Germany Founded: 1945 Workforce: 3367 Company Working: Eppendorf AG (Eppendorf) is a leading life science company that is engaged in the development of instruments, consumables, and services for liquid, sample, and cell handling in laboratories all around the globe. It offers a wide range of products that include pipettes and automated pipetting systems, spectrometers, dispensers, centrifuges, mixers, and DNA amplification equipment as well as ultra-low temperature freezers, bioreactors, CO2 incubators, fermenters, shakers, and cell manipulation systems. With these products, it serves various industries such as pharmaceutical, biotechnology, chemical, and food. The company focuses on clinical and environmental analysis laboratories, forensics, and industrial laboratories performing process analysis, production, and quality assurance. Geographically, it operates in more than 25 countries in regions such as Europe, North America, and Asia.

Company Headquarters: Texas, US Founded: 1994 Workforce: ~300 Company Working: SPI Pharma (SPI) is a subsidiary company of Associated British Foods plc (ABF), it is a part of ABF Ingredients division. SPI Pharma offers a wide range of magnesium hydroxide powders that vary in particle size and density. The company provides innovative solutions for the pharmaceutical and nutritional industries. SPI’s product line comprises antacid actives, compressible calcium powders, drug delivery systems, vaccine adjuvants, functional excipients, and taste-masked actives. The company distributes and sells its products through distributors and agents in North America, Europe, and the Middle East & Africa. The company has operations in France, the US, and India. SPI reported a sale of USD 139.31 million by the end of 2018.

| Item | Detail | |---|---| | Legal name | UBE Corporation (UBE株式会社) | | Former names | Ube Industries, Ltd. / 宇部興産株式会社 (1942 – March 2022) | | Origins / founding year | 1897 (Okinoyama Coal Mine, a silent partnership). The current corporation was incorporated in March 1942 through the merger of four Ube companies. | | Incorporation jurisdiction | Japan | | Registered head office | 1978-96 Oaza Kogushi, Ube City, Yamaguchi Prefecture, Japan | | Tokyo head office (operational HQ) | Seavans North Building, 1-2-1 Shibaura, Minato-ku, Tokyo | | Stock exchange / ticker | Tokyo Stock Exchange Prime Market: 4208. Also quoted OTC in the US (UBEOF) and in Frankfurt (UBE); both are secondary quotations. Disclosures from 2023 also referenced a Fukuoka Stock Exchange listing; the FY2026 Yuho lists only the TSE. | | ISIN / LEI | ISIN JP3158800007; LEI 529900XMRZ2VNF3ZPS69. CUSIP: not applicable (no US primary listing). | | Fiscal year end | 31 March | | Share capital | JPY 58,435 million | | Shares issued / treasury | 106,200,107 issued; 9,054,915 treasury shares (31 March 2026); about 97.15 million outstanding | | Employees (consolidated) | 7,968 at 31 March 2026. Trend: 7,882 (FY2024), 7,563 (FY2025), 7,968 (FY2026). The FY2026 increase came mainly from the LANXESS Urethane Systems acquisition. | | Employees (parent only) | 2,778 at 31 March 2026; average age 43.4 years, average tenure 15.3 years, average salary JPY 7.75 million | | Auditor | EY ShinNihon LLC; 57 years of continuous audit; FY2026 group audit fees JPY 182 million | | Market capitalisation | About JPY 306 billion, computed as JPY 3,147 close on 7 October 2026 × about 97.15 million shares outstanding excluding treasury. MarketScreener showed JPY 307 billion. | | Credit rating | JCR long-term issuer rating A (Stable), CP J-1; affirmed 30 January 2026 | | Website | https://www.ube.com | | President & CEO | Yuki Nishida (since 1 April 2025) | | Chairman | Masato Izumihara (non-executive chairman since 1 April 2025) | The entity profiled is UBE Corporation (UBE株式会社), the Japanese specialty-chemicals and machinery group formerly known as Ube Industries, Ltd. (宇部興産株式会社). This is an exact legal-name match for the input "UBE Corporation". The input listing type, "Public company", is confirmed. UBE is listed on the Prime Market of the Tokyo Stock Exchange. UBE Corporation is a 129-year-old Japanese chemicals and machinery group in the middle of a deliberate transformation from a coal-, ammonia- and caprolactam-anchored commodity producer into a global specialty-chemicals company. Its competitive core is a set of vertically integrated technology chains. The polyimide chain runs from BPDA monomer to UPILEX film, varnish and hollow-fibre gas-separation membranes. The C1 chain runs from proprietary gas-phase dimethyl carbonate (DMC) technology to polycarbonate diols, battery-grade carbonates and, since April 2025, the urethane prepolymer systems acquired from LANXESS. Silicon-nitride ceramics and lithium-ion battery separators (via 66%-owned Ube Maxell) complete the specialty portfolio. UBE also owns UBE Machinery, a die-casting and moulding-machine maker being prepared for IPO, and a 50% stake in Mitsubishi UBE Cement, Japan's No. 2 cement producer, which applied for a TSE listing in July 2026. FY2026 sales were JPY 462.3 billion and operating profit JPY 18.9 billion. Management targets JPY 100 billion+ EBITDA and ROE of 8%+ by FY2030. --- ### What the company does UBE manufactures and sells a broad range of chemical products and, through UBE Machinery, industrial machinery. From FY2026 it reports six segments: **Functional Products:** (機能品; called "Specialty Products" in some English materials): polyimide, separation membranes, ceramics, separators, phenolic resin, semiconductor gases. **High Performance Urethanes:** (高機能ウレタン): the urethane systems acquired from LANXESS, plus legacy high-performance coatings (polycarbonate diol, PCD, and polyurethane dispersion, PUD). **Pharmaceutical:** (医薬): drug discovery plus contract development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. **Resins & Chemical Products:** (樹脂・化成品; called "Polymers & Chemicals" in English materials): composites, nylon polymers, caprolactam and ammonium sulphate, industrial chemicals, C1 chemicals, elastomers. **Machinery:** (機械): die-casting machines, extrusion presses, injection-moulding machines, industrial machinery, bridges and steel structures, after-sales service. **Others:** (その他): electric power supply from in-house coal-fired generation, real estate, overseas sales companies. The cement business is not consolidated. Since 1 April 2022 it has sat inside Mitsubishi UBE Cement Corporation (MUCC), a 50:50 equity-method joint venture with Mitsubishi Materials. MUCC's contribution appears in "equity in earnings of affiliates" below operating profit: JPY 12.6 billion in FY2026 and JPY 15.6 billion in FY2025 (Source: FY2026 results presentation, 13 May 2026). ### Company's own description (FY2026 Yuho, paraphrased) The Yuho describes the group as 77 companies (the parent plus 76 affiliates at 31 March 2026). It states its purpose as "Breaking Through with the Chemistry of Hope" (希望ある化学で、難題を打ち破る) and its 2030 vision as becoming "a specialty chemicals company contributing to the global environment, people's health and an enriched future society." The medium-term plan "UBE Vision 2030 Transformation – 2nd Stage" (FY2025–FY2030 in company labelling) sets five materialities: 1. Expansion of specialty businesses 2. Activation of diverse human resources 3. Occupational safety and process safety 4. Response to global environmental issues 5. Sincere and fair corporate governance ### Business model and revenue model UBE's revenue is overwhelmingly product sales. The Yuho states that chemical revenue is recognised on delivery or risk transfer, while long-dated machinery contracts are recognised over time using an input (cost-to-cost) method. Four secondary revenue streams matter at the margin: 1. **Technology licensing.** UBE licenses its DMO (dimethyl oxalate) and MEG (monoethylene glycol) production technology to roughly 25 Chinese coal-chemical producers, with contracts dated 2010–2020. It also licenses DMC and DMC/EMC technology to at least 12 Chinese counterparties (2015–2024), and polyimide and separator technology to Panasonic Industry, SUMaterials and Ube Maxell. Management flagged lower C1 licence income as a FY2027 headwind. 2. **Machinery after-sales service.** This is described as a stable, recurring, high-margin stream, and was the main profit stabiliser in Machinery during FY2025–FY2026. 3. **Pharmaceutical royalties and contract manufacturing.** Royalty income declined in FY2025. 4. **Electricity sales** from the Ube coal-fired power plant to external customers, including MUCC's cement plants. No subscription revenue is disclosed. The product-versus-service mix is not disclosed numerically. Machinery after-sales and licence income are not broken out separately. ### Value-chain position UBE sits in the upstream-to-midstream part of the chemical value chain. - In the polyimide chain it is fully integrated from monomer (BPDA, biphenyl tetracarboxylic dianhydride) to film, varnish and hollow fibre, through to finished gas-separation modules. - In C1 it owns the core catalytic process (gas-phase methyl-nitrite route to DMC). It sells merchant DMC/EMC into battery electrolytes and semiconductor processing, and downstream into PCD/PUD coatings and now urethane prepolymers. - In nylon it has historically been integrated from benzene through cyclohexanone and caprolactam to nylon-6 polymer and compounded composites. The upstream part of this chain is being shut in Thailand (March 2026) and Japan (March 2027). - In elastomers it is a mid-sized polybutadiene producer supplying tyre makers. ### Customer types and end-markets | End-market | Representative UBE products | Notes | |---|---|---| | Electronics / displays / smartphones | Polyimide film (FPC, COF), polyimide varnish for OLED panels, BPDA, high-purity chemicals, semiconductor gases | UBE claims No. 1 global share in polyimide film for COF applications in LCD displays (company website) | | Automotive / EV / HEV | Li-ion separators (HEV-weighted), DMC/EMC electrolyte solvents, silicon-nitride bearing balls and substrates, nylon composites, polybutadiene (tyres), die-casting machines (incl. large "giga-cast" machines) | HEV demand drove separator growth in FY2026; EV slowdown hurt ceramics | | Energy / environment | CO2 separation membranes for biomethane, nitrogen membranes, low-carbon ammonia supply chain participation | Biomethane membranes hit by customer inventory adjustments in FY2026; recovery seen in Q1 FY2027 | | Industrial / mining / construction | Urethane cast elastomers (rollers, wheels, mining screens), industrial machinery (kilns, vertical mills, crushers, conveyors), bridges | Urethane systems strongest in the US | | Packaging / food | Nylon-6 for food-packaging film, polyethylene film | Weak overseas demand in FY2026 | | Agriculture | Ammonium sulphate fertiliser (by-product of caprolactam) | Shrinking with the caprolactam exit | | Pharmaceuticals | API and intermediate CDMO; drug discovery partnerships | Volumes fell 33% in FY2026 | ### Independent characterisation UBE is best understood as a "sum-of-the-parts in transition." The listed equity currently bundles five distinct things: 1. A sub-scale but technologically differentiated specialty-chemicals core (Functional Products plus Urethanes plus C1), earning roughly 9–16% segment margins. 2. A large, low-margin, cyclical "structural reform" commodity block (caprolactam, nylon, ammonia, elastomers), which generated about JPY 188 billion of sales in FY2026 at roughly breakeven. 3. A mid-cycle machinery business heading for IPO. 4. A 50% stake in a cement company heading for IPO, booked at about JPY 204 billion in investments in joint ventures. 5. A coal-fired power asset. The investment case depends on how quickly management can shrink item 2, monetise items 3 and 4, and redeploy capital into item 1 without destroying value through acquisition premiums. That last risk is real: FY2026 ROIC was 3.8% against an estimated 8% cost of equity.

Company Headquarters: Colombes, France Founded: 2003 Workforce: ~20,000 Company Working: Arkema is engaged in the manufacturing and supply of specialty chemicals and advanced materials. It operates through three segments: high-performance materials, industrials specialties, and coating solutions. The company offers value-added solutions to various markets including construction, electronics and electrical, food, agrochemicals, oil and gas, packaging and paper, renewable energies, transportation, water, health, hygiene, beauty, and sports. Hydrate inhibitors are offered under the industrial specialties segment. Arkema has 136 production sites and 15 research centers, with six R&D centers dedicated to sustainable development, in 55 countries across the globe.

Company Headquarters: Herrliberg, Switzerland Founded: 1936 Workforce: ~2,939 Company Working: EMS-Chemie Holding (EMS-Chemie) is engaged in the manufacturing and distribution of polymers and other chemical products. It operates through two business segments—high-performance polymers and specialty chemicals. The high-performance polymers segment comprises EMS-Grivory and EMS-Eftec. EMS-Grivory operates through three business units in Europe, the Americas, and Asia, and offers polyamide materials for the automotive and electrical & electronics industries, among others. The company provides polyamide 12 for numerous applications in electronics, sanitary fittings, fuel & air brake lines, and sheathing for fiber optical waveguides, and food & beverages. The company operates 26 production sites in around 16 countries, and sells products worldwide through distributors/traders.

Company Headquarters: Paris, France Founded: 1929 Workforce: ~ 5,400+ Company Working: Ipsen Pharma is a global pharmaceutical company operating in two segments, namely, specialty care and consumer healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rare disease areas. In the neuroscience segment, the company provides products for the treatment of cervical dystonia, adult spasticity, blepharospasm, hemifacial spasm, hyperhidrosis, and pediatric lower limb spasticity. Ipsen Pharma operates as a subsidiary of Mayroy S.A. The company has R&D centers and manufacturing sites located in China, France, Ireland, the UK, and the US. Ipsen Pharma is present in more than 115 countries and has a direct presence through corporates offices in around 35 countries across the globe.

Company Headquarters: Massachusetts, US Founded: 1984 Workforce: 11-50 Employees Company Working: Safety 1st is a subsidiary of Dorel Industries Inc. The company deals in home security products, child safety products and childcare, and convenience and activity products. Safety 1st is known for its famous yellow BABY ON BOARD sign. It supplies a lot of novel and innovative products to parents to help them in keeping their child safe. As the company is privately held, the financial information mentioned is of the parent company, Dorel Industries

Company Headquarters: Georgia, US Founded: 1942 Workforce: 500-1000 Employees Company Working: Graco Children’s Products Inc. is a subsidiary of Newell Brands. It is a recognized leader of manufacturing baby products. The company provides thoughtful, practical, and dependable parenting solutions to families. It manufactures intuitive and user-friendly products. Its product range includes strollers, car seats, high chairs, playards, monitors, swings, soothers, activity center products, travel systems, audio digital/audio analog/prenatal monitors, doorway jumpers, nursery care products, and many more.

Company Headquarters: Chicago, US Founded: 1928 Workforce: 10000+ Employees Company Working: Motorola Home provides numerous products in the global market such as modems and networking, chargers and power banks, cases, music and sound, cordless phones, and baby monitors. The company has a strong brand name and distribution network all over the world.

Company Headquarters: Canada Founded: 1991 Workforce: 200 Employees Company Working: The company is into the development and manufacturing of video security systems. Lorex Technology Inc. provides cloud-based security systems for personal as well as corporate use. The company operates in segments such as security cameras, wireless security cameras, internet protocol cameras (IP cameras), security digital video recorder (DVR), security camera systems, HD security camera system, and lorex security camera accessories Lorex Technology Inc. is a subsidiary of FLIR Systems Inc. Hence, the below financial information provided is of FLIR Systems Inc.

Company Headquarters: Massachusetts, US Founded: 1949 Workforce: 150+ Employees Company Working: The first years Inc. is a global juvenile products brand. The company is a major manufacturer and distributor of baby care products. The company operates in three segments, namely, feeding and soothing, play and discover, and care and safety. The company also offers products such as bathing and grooming products, toys, teethers, bath toys, books, stroller toys, and rattles. The first years Inc is a subsidiary of RC corporation which is under the control of Tomy Company, Ltd. Hence, the below financial information provided is of Tomy Company, Ltd.

Zeria Pharmaceutical is a mid-capitalisation Japanese pharmaceutical company that has executed one of the more complete internationalisation transitions in its peer group. Founded in 1955 around a chondroitin preparation, it built a dual-engine model — prescription gastroenterology plus consumer self-medication — and then, through the 2009 acquisition of Switzerland's Tillotts Pharma AG and the 2020 purchase of Dificlir's European marketing authorisations from Astellas, converted itself from a domestic specialist into a company that now earns 59.3% of revenue outside Japan. Ranked 23rd by revenue among 35 major listed Japanese pharmaceutical companies, it nonetheless posts a 13.9% operating margin that exceeds most similarly sized peers, several of which recorded operating losses in FY2026. The strategic question is no longer whether Zeria can globalise, but whether it can replace Dificlir — its second-largest product, facing patent expiry inside the current medium-term plan — before the earnings contribution rolls off. | Metric | FY2024 | FY2025 | FY2026 | |---|---|---|---| | Employees consolidated | 1746 | 1746 | 1748 | | Employees parent only | 872 | 872 | 872 | *Note: GlobalData reports 1,746 consolidated employees against an unspecified reference date; the company's own outline page reports 1,748 as at 31 March 2026. The parent-company and prior-year headcounts above are drawn from filing aggregator summaries; the precise FY2024 and FY2025 splits should be confirmed against the respective Annual Securities Reports before use in a published document. Headcount has been essentially flat for three years, which is itself the notable fact: Zeria has grown revenue roughly 18% over that period without material headcount addition, with growth carried by European subsidiary productivity and price/mix rather than sales-force expansion.* --- ### What the company does Zeria Pharmaceutical researches, develops, manufactures, imports, exports and sells pharmaceuticals, quasi-drugs, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals and reagents; and cosmetics, health foods, alcoholic and soft beverages, food additives, feed, fertiliser, hygiene sundries, medical devices, health equipment, sanitary fixtures, beauty appliances, and measuring and analytical instruments. That is the articles-of-incorporation description; in economic substance the group does two things, and a rounding error. **The prescription business** is a gastroenterology franchise. Zeria describes its ethical-drug strategy as specialising "from research and development through to sales in the gastrointestinal field, covering the upper to lower gastrointestinal tract," with oncology selected as the second focus area behind gastroenterology. In Japan the company fields its own MR (medical representative) organisation through seven branch offices; in Europe it sells through the wholly owned Tillotts Pharma network of nine legal entities; in Asia it exports and works through the Vietnamese subsidiary F.T. Pharma and third-party distributors. **The consumer healthcare business** manufactures, procures and sells OTC medicines, health foods, quasi-drugs and cosmetics supporting self-medication. It is overwhelmingly a Japanese business, anchored on three brand families — Hepalyse (liver-hydrolysate tonics and drinks), Chondroitin (joint and back-pain preparations), and With One (botanical laxatives) — supported by dermatology, oral care, Western herbal medicines and the Iona cosmetics line. **The "Other" segment** is insurance agency and real-estate rental income, generating ¥151m in FY2026 — 0.17% of group revenue. It is not investible and exists largely as a legacy holding structure. ### Business model and revenue model Zeria's revenue is essentially 100% product sales. There is no meaningful service, subscription or SaaS-analogue revenue. Licensing income exists but is not separately disclosed at a level suggesting materiality; the Z-338/acotiamide out-licensing programme to Faes Farma, Meiji Seika Pharma, Agastra-Lab and others generates milestone and royalty flows that are absorbed into segment results without separate line-item disclosure. Revenue is recognised on customer acceptance for most transactions, and on shipment for domestic sales where the shipment-to-acceptance interval is normal. Consideration is measured net of returns, discounts and rebates; variable consideration is estimated to the extent significant reversal is improbable. Customer loyalty points issued by certain subsidiaries are identified as separate performance obligations. Consideration is collected within one year, so there is no significant financing component. Two structural features of the model deserve emphasis: **First, the gross margin is very high and the operating margin is not.** FY2026 gross margin was 73.1%; operating margin was 13.9%. The 59-point gap is SG&A, which ran at ¥52,808m, or 59.2% of revenue. This is a marketing-intensive, not a manufacturing-intensive, business. Advertising and promotion alone is budgeted at ¥3,100m for FY2027 against ¥2,440m spent in FY2026 — a 27% planned increase. **Second, a substantial share of the group's economic value sits in acquired intangibles rather than in tangible plant.** At 31 March 2026, intangible fixed assets stood at ¥39,582m — 22% of total assets and 43% above the ¥27,599m carrying value of all tangible fixed assets. Of that, ¥27,089m is *marketing rights* (販売権) and ¥7,822m is *trademarks*. The marketing-rights balance is dominated by the Dificlir authorisations acquired from Astellas. This is the single most important balance-sheet fact about Zeria, and Section 18 returns to it. ### Value chain position, customers and end markets Zeria occupies the branded-originator and in-licensor position. It is not a generic manufacturer, not a CDMO, and not a wholesaler. It sits between upstream API and contract manufacturing (a dependency demonstrated in FY2026, when a contract manufacturer's production-equipment fault caused an Asacol supply shortage that suppressed overseas sales through Q3) and downstream distribution. Customer types by channel: **Japan ethical:** pharmaceutical wholesalers supplying hospitals, clinics and dispensing pharmacies. Reimbursement is set by the national NHI price list, which is revised on a schedule that has become effectively annual — a recurring negative disclosed in every recent results commentary. **Europe ethical:** national wholesalers and, in tender markets, hospital and payer procurement bodies, served through Tillotts entities in the UK, Ireland, Sweden, Denmark, Germany, France, Spain, Italy and the Czech Republic. **Japan consumer:** drugstore chains, dispensing pharmacies, convenience-store chains (a distinct and strategically important channel for the Hepalyse W range), general merchandise retailers, and a direct-to-consumer e-commerce operation (Zeria Online). **Asia:** distributors, plus F.T. Pharma's own domestic Vietnamese channel including a new infusion-solution plant. End markets served: inflammatory bowel disease (ulcerative colitis, Crohn's disease); *Clostridioides difficile* infection; functional dyspepsia; gastritis and peptic ulcer; iron-deficiency anaemia; hyperkalaemia; hypophosphataemia; hypertension; pain and inflammation; ophthalmology; underactive bladder (development stage); non-small-cell lung cancer (development stage); and the Japanese self-medication market across tonics, digestive health, joint health, constipation, cold remedies, dermatology, oral care, femcare and cosmetics. ### Independent characterisation Read without the company's framing, Zeria is best understood as a Japanese-listed holding structure around a European specialty gastroenterology business, cross-subsidised and de-risked by a mature, cash-generative Japanese consumer brand portfolio. The numbers support this reading more strongly than the company's own "two wheels of a cart" (車の両輪) balanced-portfolio narrative. In FY2026 the ethical segment produced ¥61,626m of revenue and ¥12,176m of segment profit; consumer healthcare produced ¥27,382m and ¥6,360m. But ethical is where all the growth is (+4.5% versus −2.8%), and within ethical, overseas is where all of *that* growth is: Japan revenue fell 3.4% to ¥36,318m while overseas rose 6.3% to ¥52,841m. The Japanese consumer business is a declining-to-flat annuity that funds European expansion and absorbs corporate overhead; the interesting asset is Tillotts. This matters for valuation because the market appears to be pricing the consolidated entity as a Japanese mid-cap OTC company — 0.85x book, ~9x forward earnings — rather than as a European specialty pharma with a 22% EBITDA margin and a 59% net-debt-to-EBITDA ratio. The counter-argument, which the market may be right about, is the Dificlir patent cliff.

Company Headquarters: Cologne, Germany Founded: 1864 Workforce: ~4,645 Company Working: Deutz AG is a leading manufacturer and supplier of innovative drive systems such as diesel, gas, and electric drivetrains for professional applications. The company offers a wide range of engines with a capacity up to 620 kW, which are used in various applications including agricultural machinery, construction equipment, material handling equipment, commercial vehicles, stationary equipment, and rail vehicles. It operates through seven business segments, namely, construction equipment, service, material handling, agricultural machinery, stationary equipment, automotive, and miscellaneous. The company offers BMS through its subsidiary, Futavis GmbH (Germany). Deutz AG has its presence in more than 130 countries across the world. Moreover, the company offers products to its clienteles through 13 distribution companies, 7 sales offices and over 800 sales and service partners, globally.

Company Headquarters: Esslingen, Germany Founded: 1865 Workforce: ~9,862 Company Working: Eberspächer is engaged in manufacturing and supplying a wide range of products, including fuel operated heaters, exhaust systems, electrical heaters, automotive controls, and air conditioning in the global market. It is also engaged in developing BMSs for smart-sustainable grid, green-renewable energy storage, and electric vehicle power applications. The company operates through three business segments, namely, exhaust technology, climate control systems, and automotive controls. It offers BMSs under its automotive controls segment through its subsidiary, Eberspaecher Vecture Inc. (Canada). It also provides vehicle power and performance management system, control units, and electronics modules for vehicle air-conditioning systems and extended vehicle functions under this segment. The company manufactures and supplies systems, sub-systems, and related components that are used in BMSs for applications in medical, defense, industrial, and renewables, among others. Eberspächer has operations in more than 80 countries worldwide, including the US, Mexico, Brazil, South Africa, Denmark, France, Germany, Italy, Russia, China, Japan, India, and Spain.

Ecolab is the world's largest pure-play provider of water treatment, hygiene and infection-prevention solutions. It sells mission-critical chemistry, dispensing and monitoring equipment, digital analytics and on-site service, mostly under recurring, programme-based customer relationships. FY2025 net sales were $16.08bn. The mix by segment was: - Global Water: about 49% - Global Institutional & Specialty: about 38% - Global Pest Elimination: about 8% - Global Life Sciences: about 5% The company says it helps protect about one-third of the world's food production and about a quarter of global power generation. Under CEO Christophe Beck, Ecolab is moving its portfolio toward higher-growth, higher-margin "growth engines": Global High-Tech, Life Sciences, Pest Elimination and Ecolab Digital. The pivot accelerated in 2025–26 with two acquisitions: - Ovivo Electronics (ultrapure water for semiconductor fabs) - CoolIT Systems (direct-to-chip liquid cooling for AI data centres) Together these make Ecolab a full-stack "water-for-AI" supplier. The equity is valued as a quality compounder at about 34x 2026 adjusted EPS. The investment case rests on 12–15% EPS growth with margins above 20%. --- ### Company's own description (paraphrased from the FY2025 10-K and 2026 releases) Ecolab describes itself as a global leader in water, hygiene and infection-prevention solutions and services that protect people and vital resources. It says it combines science-based solutions, data-driven insights, AI technology and on-site service so that customers can define best-in-class operations and scale them across sites. The company lists its served markets as food, hospitality, healthcare, data centres, microelectronics, life sciences and heavy industry. It positions itself as "the world's water company" in the AI value chain, with three roles: - ultrapure water for chip fabrication - water treatment for the power plants that supply AI - direct liquid cooling for high-density compute Its 2030 impact goals are to help protect 2 billion people from infections and to conserve enough drinking water for 1 billion people (Q2-2026 release, "About Ecolab"). ### Business model and revenue model Ecolab's model is a razor/razor-blade service model with three layers: 1. **Consumable chemistry.** Detergents, sanitisers, water-treatment chemicals, process aids, pest products and purification resins. These are replenished continuously and drive most revenue and gross profit. 2. **Equipment.** Dispensers, controllers, sensors and liquid-cooling hardware. These are often placed at customer sites under lease or service arrangements, which creates switching costs. 3. **Field service and digital.** The 25,000-plus sales-and-service workforce audits, optimises and documents outcomes such as water saved, energy saved and regulatory compliance. Ecolab Digital (software and enabling hardware subscriptions) is a fast-growing overlay. **Characterisation of the mix:** - About 78% of revenue is product and equipment, though much of it is contractually recurring. - About 22% is service and lease. - Subscription revenue is a small but fast-growing slice. Ecolab Digital sales were $121m in Q2-2026, up 27% (8-K, 28 Jul 2026), implying a run-rate of roughly $0.45–0.5bn. - Licensing is not material. - The single largest product class is warewashing, at about 13% of FY2025 consolidated sales (10-K FY2025). ### Value-chain position Ecolab sits downstream of commodity and specialty chemical producers. Its main inputs are: - caustic soda, surfactants, phosphonates and polymers - solvents and resins - energy and plastics packaging It formulates, packages and distributes its products. It then captures margin through application know-how and service rather than molecule ownership. Pricing power comes from three sources: - customer total-cost-of-operation savings, which Ecolab quantifies as "value pricing" - the low cost of chemistry relative to the customer processes it protects (food safety, uptime, compliance) - embedded equipment and digital monitoring The 2026 energy surcharge shows both the pass-through ability and its lag. Organic gross margin dipped in early 2026 and then stabilised within one quarter (Q2-2026 release). ### Customer types and end-markets | End-market cluster | Typical customers | Segment | |---|---|---| | Heavy industry | Power generation, refining and downstream, chemicals, mining, primary metals | Global Water (Heavy Water) | | Light industry and commercial water | Manufacturing, commercial buildings, institutional campuses | Global Water (Light Water) | | High-Tech | Semiconductor fabs (ultrapure water), hyperscale and colocation data centres (cooling water, direct liquid cooling) | Global Water (High-Tech) | | Food & beverage processing | Dairy, protein, beverage, brewing, packaged food | Global Water (Food & Beverage) | | Pulp & paper | Paper and board mills | Global Water (Paper) | | Hospitality and foodservice | Full-service restaurants, hotels, lodging, contract foodservice | Global Institutional & Specialty | | Healthcare | Hospitals, long-term care | Global Institutional & Specialty (healthcare moved here in the 2025 realignment) | | Quick-service restaurants and food retail | QSR chains, grocery | Global Institutional & Specialty (Specialty) | | Pest-sensitive commercial sites | Restaurants, food retail, food plants, hospitality | Global Pest Elimination | | Biopharma and personal care | Bioprocessing, pharmaceutical manufacturing, personal care, industrial purification | Global Life Sciences | ### Independent characterisation Ecolab is best understood as a service-intensive specialty-chemicals compounder with three core features: - a defensive base: hospitality, food safety and healthcare hygiene, about 45% of sales - a cyclical but sticky industrial water franchise (Nalco, acquired 2011) - a set of secular-growth options FY2025 organic growth was about 3%. The company's long-term algorithm is 5–7% organic growth, 100–150 bps of annual operating-margin expansion, and 12–15% adjusted EPS growth. The 2026 acquisitions deliberately raise exposure to AI capital-expenditure cycles. That improves the growth mix but adds cyclicality and technology risk not historically present in the franchise.

Company Headquarters: Paris, France Founded: 1858 Workforce: ~88,775 Company Working: SUEZ specializes in providing water and waste management products and services. The company operates through five business segments, namely water Europe; recycling & recovery Europe; international; water technologies & solutions (WTS); and others. It offers chemicals, equipment, services (water distribution & treatment, and consulting), and engineering and construction contracts. Coagulants are offered under the water technologies & solutions business segment for applications such as industrial waste streams and influent clarification systems. It has operations in Europe and internationally.

Kemira is a Helsinki-headquartered, mid-cap specialty and commodity-adjacent chemicals producer that describes itself as a global leader in sustainable chemistry for water-intensive industries. With FY2025 revenue of EUR 2,753.5M and operative EBITDA of EUR 524.6M (19.1% margin), it is among the world's largest suppliers of water-treatment coagulants and polyacrylamide polymers. It is also a leading supplier of pulp bleaching chemicals (sodium chlorate, hydrogen peroxide) and of process and functional chemicals for packaging board, tissue and paper. After divesting Oil & Gas in February 2024, Kemira reorganised into three business units on 1 January 2025: Water Solutions (≈44% of revenue), Packaging & Hygiene Solutions (≈35%) and Fiber Essentials (≈20%). Its strategic ambition is to double water-related revenue, including a 2025 entry into US industrial water-treatment services. It also pursues EUR 500M+ of renewable-solutions revenue by 2030. The company is financially conservative (net debt/operative EBITDA 1.0x at end-2025) and is anchored by Oras Invest. In 2026 it is navigating a sharp, Iran-war-driven raw material and logistics cost shock. --- ### Company self-description (latest annual reporting, FY2025) Kemira presents itself as a global leader in sustainable chemistry for water-intensive industries. It serves municipal and industrial water-treatment customers and the fiber industry. Its solutions are positioned around securing clean water and supporting customers' circularity and resource-efficiency goals across their value chains. Its strategic pillars (as communicated since the 2024 strategy update) are profitable growth, with water as the principal growth engine, and renewable (bio-based) solutions as a long-term differentiation axis. ### Independent characterisation Kemira is best understood as a process-chemicals manufacturer with a "local-for-local" asset base. It operates 58 manufacturing facilities globally (FY2025 Board of Directors' Review). Its products are high-volume, relatively low-value-per-tonne chemicals (iron- and aluminium-based coagulants, sodium chlorate, hydrogen peroxide, caustic soda) where freight costs make proximity to customers a structural moat. These sit alongside higher-value functional chemistries (polyacrylamide flocculants, sizing agents such as AKD wax, dry- and wet-strength resins, defoamers, biocides, barrier chemistries). Value is added through application know-how, on-site service and, increasingly, digital dosing optimisation. The company's revenue model is overwhelmingly product sales under supply contracts. Water Solutions' municipal business is dominated by tendered, often fixed-price contracts, which explains the lag in passing through cost inflation highlighted in Q2 2026. Fiber Essentials sells bleaching chemicals under long-term agreements to pulp mills, in some cases from chemical "islands" co-located with customer mills. A nascent services revenue stream has been created through the acquisitions of Water Engineering, Inc. (October 2025), AquaBlue, Inc. (January 2026) and the Clear Water Technologies, LLC business (June 2026). These provide recurring industrial water-treatment programmes (boilers, cooling towers, wastewater) to food & beverage, healthcare, manufacturing, data-centre and commercial/institutional customers. Licensing revenue is immaterial and not separately disclosed. ### Revenue model mix (indicative) | Revenue type | Assessment | Basis | |---|---|---| | Product sales (chemicals) | Vast majority (>95%, analyst estimate) | Segment descriptions FY2025 | | Services (industrial water-treatment programmes) | Small but growing; Water Engineering acquired for approx. USD 150M; AquaBlue (<USD 10M deal value); Clear Water Technologies (2025 revenue slightly >USD 3M) | Company releases 2025–2026 | | Contract manufacturing | Included in Water Solutions "Industrial" segment (contract manufacturing for the acquirer of the Oil & Gas business) | FY2025 bulletin | | Licensing / subscription / digital | Not separately disclosed; digital services (e.g., KemConnect-type monitoring) bundled with chemistry | Company website | ### Value chain position Kemira sits in the mid-stream of the chemical value chain. It purchases basic inputs and converts them into formulated or commodity-grade process chemicals. Inputs include iron and aluminium sources (including industrial by-products such as iron sulphate from steel and TiO2 production), acrylonitrile/acrylamide-based monomers (oil-derived), electricity (critical for sodium chlorate electrolysis), salt, and fatty acids for AKD. Approximately one-third of raw materials are oil-based and mainly used for polymer production (June 2026 investor newsletter). Kemira is backward-integrated in electricity in Finland through shareholdings in Pohjolan Voima and Teollisuuden Voima (Mankala principle: power at production cost). This is a key cost advantage for energy-intensive sodium chlorate production. ### Customer types and end-markets | End-market | Customer type | BU | |---|---|---| | Municipal drinking water and wastewater | Water utilities, municipalities (Urban EMEA 26% and Urban Americas 23% of WS revenue) | Water Solutions | | Industrial water and wastewater | Manufacturing, food & beverage, mining, biogas/bioethanol, contract manufacturing (Industrial = 51% of WS revenue) | Water Solutions | | Industrial water services | Data centres, healthcare, commercial/institutional, property management | Water Solutions (New Ventures & Services) | | Packaging board, tissue, printing & writing paper | Board, tissue and paper mills (EMEA 43%, Americas 36%, APAC 21% of P&H revenue) | Packaging & Hygiene Solutions | | Bleached chemical pulp | Pulp producers (bleaching ≈70%, other base chemicals ≈30% of FE revenue) | Fiber Essentials | | Pharma intermediates | Sodium borohydride (Äetsä, Finland) | Fiber Essentials / specialty | | Textile fibre (emerging) | Metsä Group Kuura collaboration | Renewable solutions |

Company Headquarters: UK Founded: 1915 Workforce: 2901 Company Working: Ricardo delivers consulting services as well as a solution built on sustainable technological innovation. The company server is the 8 key market segments: automotive, aerospace & defense, financial services, energy utilities, and waste, public and government sectors. The company serves various markets such as aerospace and defense, energy, utilities, and waste, automotive, maritime, industrial, and manufacturing, rail and mass transit, and financial services. The company offers services such as strategic consulting, environmental consulting, technical consulting, niche production, and assurance and testing. The solution offered by the company includes corporate sustainability, energy decarbonization, air quality and urbanization, policy, strategy and economics, emerging mobility, water management, rail independent assurance, propulsion system engineering, rail engineering and operation, powertrain system production, defense system engineering, and driveline production.

Company Headquarters: Fort Worth, Texas Founded: 1945 Workforce: 10,001+ Company Working: Alcon, Inc., being a truly global company, works in over 70 countries and serve patients in more than 140 countries. It also develops and manufactures medicines and devices for eye care. The company offers a line of ophthalmic surgical devices and ocular health products, as well as viscoelastic, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery.

Company Headquarters: Alpharetta, Georgia Founded: 2008 Workforce: 11-50 Company Working: Visioneering Technologies, Inc. (VTI) is an innovative company which is dedicated to redefining vision by bringing together clinical, marketing, engineering, manufacturing, and regulatory leaders from today’s top vision care businesses. With a portfolio of technologies to address eye care issues such as presbyopia, myopia, and astigmatism, the company uses creative and differentiated design approaches to develop products that would ultimately enhance the experiences of practitioners and patients.